Mutations in ATP8B1, a broadly expressed P-type ATPase, result, through unknown mechanisms, in disorders of bile secretion. These disorders vary in severity from mild and episodic to progressive with liver failure. We generated Atp8b1 G308V/G308V mutant mice, which carry a mutation orthologous to that present in homozygous form in patients from the Amish index kindred for severe ATP8B1 disease. In contrast to human patients, Atp8b1 G308V/G308V mice had unimpaired bile secretion and no liver damage, but showed mild abnormalities including depressed weight at weaning and elevated serum bile salt levels. We challenged the hepatobiliary metabolism of Atp8b1 G308V/G308V mice by administering exogenous bile salts. Upon bile salt feeding, Atp8b1 G308V/G308V mice, but not wild-types, demonstrated serum bile salt accumulation, hepatic injury and expansion of the systemic bile salt pool. Unexpectedly, this failure of bile salt homeostasis occurred in the absence of any defect in hepatic bile secretion. Upon infusion of a hydrophobic bile salt, wild-type mice developed cholestasis while Atp8b1 G308V/G308V mice maintained high biliary output and more extensively rehydroxylated the infused bile salt.
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mutations' effects on protein function likely contributes to the phenotypic differences between these syndromes; however, the episodic nature of BRIC implicates unknown environmental variables in the expression of these mutations.
Defects in BSEP also cause PFIC (15) . The forms of PFIC associated with ATP8B1 and with BSEP differ in that patients with ATP8B1 defects have milder liver damage, but suffer from extrahepatic complications, such as secretory diarrhea and pancreatitis, that are not ameliorated by liver transplantation (16) (17) (18) (19) . Consistent with these clinical observations, ATP8B1 is broadly expressed in epithelial tissues, with particularly high expression levels in the small intestine and pancreas (14) . The mouse orthologue, Atp8b1, has been localized to apical membranes of hepatocytes, bile duct and intestinal epithelial cells (cholangiocytes and ileocytes), and panc reatic acinar cells (20, 21 , L. Klomp, personal communication). In contrast, BSEP is present primarily in the hepatocyte canalicular membrane in humans and rodents (2-3).
As cholestasis is the primary manifestation of BRIC and PFIC, it was surprising that ATP8B1 is not homologous to known bile salt transporters. It belongs to P-type ATPase subfamily IV (14) . Some members of this subfamily flip aminophospholipids from the outer to the inner leaflet of the plasma membrane to maintain its asymmetric lipid distribution (22) .
ATP8B1 also may possess such activity (21) . Members of subfamily IV are implicated in protein trafficking (23, 24) and apoptosis (22) . ATP8B1 is the first type IV P-type ATPase implicated genetically or functionally in human disease (25) .
We generated mice homozygous for a mutation in Atp8b1, the mouse orthologue of ATP8B1 , reproducing the ATP8B1 G308V point mutation seen in the Amish PFIC kindred (14) .
The Atp8b1
G308V/G308V mice suffer from deranged bile salt homeostasis leading to an expanded bile salt pool and hepatic injury, despite the absence of any defect in canalicular bile secretion.
at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from Pawlikowska 5 We hypothesize that the expansion of the bile salt pool is caused by increased bile salt resorption.
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RESULTS

Generation of Atp8b1 G308V/G308V mutant mice
We isolated the mouse orthologue of ATP8B1 and found that Atp8b1 exhibits 86% DNA identity and 98% amino acid similarity to ATP8B1. We designed a targeting vector, Atp8b1G923Tneo , to introduce into Atp8b1 the G923T mutation (resulting in a G308V substitution in a glycine conserved between human and mouse) found in many Amish PFIC patients (14) . Gene targeting in mouse ES cells achieved germ-line transmission of the Atp8b1G923Tneo allele (Fig. 1A, B) .
Deletion of the neo selection cassette was confirmed. Heterozygous mice were intercrossed to produce Atp8b1 G308V/G308V homozygous mutants ( Fig. 1C ), which were born at the expected frequency, indicating Atp8b1 was not required for embryonic development. Atp8b1
G308V/G308V
mice were fertile; their lifespan did not differ from that of strain-matched wild -types.
The gene targeting approach was not expected to affect Atp8b1 transcription, and indeed normal levels of Atp8b1 mRNA were seen in liver and ileum of Atp8b1 G308V/G308V mice (RT-PCR, data not shown). Western blotting revealed that Atp8b1 mutant mice had no detectable Atp8b1 in the liver and only traces in the ileum (Fig. 1D) . The G308V mutation thus resulted in loss of Atp8b1 in mice, reproducing the defect seen in fibroblasts from a PFIC patient with the orthologous mutation (unpublished data).
Atp8b1
G308V/G308V mice have delayed growth and hepatic abnormalities
Loss of Atp8b1 impaired pup growth in the nursing period, as Atp8b1 G308V/G308V pups gained weight more slowly than their wild-type and heterozygous littermates ( Table 1 ). The weight difference resolved with age, and adult Atp8b1 G308V/G308V mice appeared normal. Unlike human patients with the corresponding mutation (10, 11, 14) , Atp8b1 G308V/G308V mice did not suffer from jaundice or diarrhea and had normal serum bilirubin levels and normal liver enzyme activities, except for mildly elevated serum AST (aspartate aminotransferase) activity (Table 1) . Their slightly enlarged livers suggested mild hepatic stress, but light microscopy revealed no histological abnormalities (data not shown). Atp8b1 G308V/G308V mice showed elevated serum bile salt levels (Table 1) , confirming Atp8b1 involvement in bile salt homeostasis.
Endogenous biliary bile salt secretion of Atp8b1 G308V/G308V mice is unimpaired
To investigate bile secretion in Atp8b1 G308V/G308V mice, we collected bile by gallbladder cannulation after distal ligation of the common bile duct. Contrary to expectation, biliary bile salt concentration was not reduced, and bile flow as well as output of principal bile components was mildly enhanced (Table 1) . Atp8b1 mutants had a slightly more hydrophilic biliary bile salt composition than wild-types, with a higher proportion of muricholate and lower proportion of cholate (Table 1) .
Atp8b1
G308V/G308V mice display unimpaired transhepatic bile salt transport and are resistant to bile salt-induced cholestasis
To characterize hepatic bile salt transport in Atp8b1 G308V/G308V mice, we intravenously infused hydrophilic or hydrophobic bile salts into mice whose endogenous bile salt pool had been depleted by bile drainage. During bile salt pool depletion, biliary bile salt secretion was significantly higher in mutants than in wild -types. Intravenous infusion of tauroursodeoxycholate (TUDC), a hydrophilic, choleretic bile salt, confirmed that transhepatic bile salt transport and the biliary bile salt secretion capacity of Atp8b1 mutant mice were unimpaired; biliary bile salt output was no lower in Atp8b1 G308V/G308V mice than in wild-types even at the maximal TUDC infusion rate ( Fig. 2A) . In wild-type mice, cholate feeding had no deleterious effects, but strongly up-regulated Atp8b1 expression in ileum and mildly up-regulated Atp8b1 expression in liver (Fig. 3A) .
Cholate-fed Atp8b1 G308V/G308V mice lost weight (Fig. 3B) . Their serum bilirubin concentration and liver enzyme activity levels rose, compared to wild-types ( Fig. 3C and 3D mice We compared biliary bile salt output between wild-type and Atp8b1 G308V/G308V mice on control ( Fig. 2A ) and cholate-supplemented (Fig. 4) diets. In wild-type mice, cholate feeding did not significantly affect biliary bile salt output. In contrast, cholate-fed mutants increased their bile salt output, compared to mutants fed a control diet, as well as to wild-types on a cholatesupplemented diet. Subsequent intravenous infusion of TUDC induced a parallel rise in bile salt output in cholate-fed mice of both genotypes (Fig. 4 ). These data demonstrate that serum bile salt accumulation in cholate-fed Atp8b1 G308V/G308V mice does not result from a defect in either hepatic uptake or canalicular secretion.
Cholate -fed Atp8b1 G308V/G308V mice retain high levels of orally administered 3 
Htaurocholate
To investigate why Atp8b1 G308V/G308V mice accumulate bile salts upon cholate feeding, we administered an oral dose of 3 H-la beled taurocholate to mice equilibrated to control or cholatesupplemented diets, and determined total residual 3 H levels after 4 days. 3 H levels were similar in wild-types and mutants on control diet. However, on cholate-supplemented diet, total residual Pawlikowska 10
We also compared proportional distributions of 3 H among the organs of the enterohepatic circulation between wild-type and mutant mice on cholate diet (Fig. 5B ). If canalicular bile salt secretion were defective, accumulation of label in the liver of mutant mice would be expected.
However, a much larger proportion of the label was found in the gallbladder bile of Atp8b1 G308V/G308V mice than in the gallbladder bile of wild -type mice, and a relatively smaller proportion in mutant mouse liver. These experiments confirmed, in the physiologically relevant context of an intact enterohepatic circulation, that hepatic secretion is not impaired in Atp8b1 mutant mice.
Atp8b1 G308V/G308V mice have an enlarged bile salt pool
To characterize further the de ranged bile salt homeostasis in Atp8b1 G308V/G308V mice, we measured the size of the bile salt pool. Under control conditions, the bile salt pool of mutant mice was enlarged over 2-fold compared to wild-types. Bile salt feeding increased pool size in all mice, but the increase was more dramatic in Atp8b1 G308V/G308V mice, resulting in a bile salt pool more than 4-fold larger than in cholate-fed wild-types (Fig. 6A ). Atp8b1 mutant mice were thus unable to maintain an appropriate bile salt pool size upon dietary bile salt challenge.
We analyzed the fecal bile salt composition of control and cholate-fed mice, which provides an indirect measure of bile salt synthesis. Total fecal bile salt output was similar in mutant and wild-type mice under both conditions; cholate feeding increased the fecal bile salt output 10-fold in both genotypes (Fig. 6B ). Under control conditions, the fecal bile salt composition of Atp8b1 G308V/G308V mice was more hydrophilic than in wild-types, consistent with the mild changes seen in biliary and serum bile salt pool composition (Fig. 6C) 
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Atp8b1 mutants and wild-types. (Fig. 6D ). However, cholate-fed Atp8b1 mutants had 9-fold higher fecal levels of taurocholate than wild-types, as well as higher levels of other tauroconjugated bile salts. This indicated that enhanced resorption and hepatic conjugation of the fed cholate occurred in the Atp8b1 mutants. All mice had only trace amounts of lithocholate in their feces. However, cholate-fed Atp8b1 G308V/G308V mice excreted less lithocholate and taurolithocholate than wild-types.
Effects of Atp8b1 mutation on expression levels of genes involved in bile salt homeostasis
To investigate the molecular mechanisms underlying the perturbed bile salt homeostasis in Atp8b1 G308V/G308V mice, we employed real-time quantitative PCR to evaluate hepatic and ileal mRNA expression of genes involved in the regulation of bile salt synthesis and transport. with near-complete down-regulation of hepatic bile salt synthesis in response to dramatically elevated systemic bile salt levels (Fig. 7B) .
We also evaluated expression of hepatic bile salt transporters. Loss of Atp8b1 did not significantly affect hepatic Bsep expression, consistent with the unimpaired biliary bile salt output in Atp8b1 G308V/G308V mutant mice. Mutant mice had slightly lower Ntcp expression than wild-types under both control and cholate-fed conditions, suggesting mild repression of hepatocyte bile salt uptake, consistent with response to increased serum bile salt levels.
Expression of Asbt (which is present in cholangiocytes, but not in hepatocytes) was not significantly different between Atp8b1 mutants and wild-types under either condition (Fig. 7B ).
However, hepatic Asbt expression was three times lower in cholate-fed mutants than in controlfed wild -types, suggesting an interaction between Atp8b1 genotype and cholate diet in cholangiocytes.
In the terminal ileum, Atp8b1 mutation had no significant effect on mRNA expression of four receptors involved in bile salt sensing (Fxr, Lxr, Car, Vdr) under control or cholate-fed conditions (Fig. 7C ). Ileal Pxr expression in Atp8b1 G308V/G308V mice was mildly increased upon cholate feeding; this effect was less pronounced than in liver. There was no difference in ileal expression of Asbt, the primary transporter mediating ileal resorption of conjugated bile salts (4-7), between wild-type and Atp8b1 G308V/G308V mice on either diet (Fig. 7C ). This observation was confirmed by Western blot (data not shown). As expected, expression of the ileal lipid binding protein Ilbp increased in response to cholate feeding in all mice (28, (33) (34) ), but we detected no difference between Atp8b1 G308V/G308V mutants and wild-types (Fig. 7C) . 
DISCUSSION
We generated mice homozygous for the G308V point mutation in Atp8b1 , the first targeted mouse mutants for a member of P-type ATPase subfamily IV. This mutation likely results in a structurally unstable and rapidly degraded protein. The orthologous mutation, present in the Amish pedigree in which PFIC was first described (10, 14) , results in an analogous loss of ATP8B1, indicating that G308V is a functional null mutation in both mice and humans. and Ntcp confirmed the unimpaired regulatory response of the Atp8b1 mutant liver to bile salt challenge; these genes are directly or indirectly regulated by Fxr, the nuclear receptor that has bile salts as ligand (33, 34) . In Atp8b1 mutants, but not in wild-types, bile salt feeding also induced significant changes in hepatic expression of the bile salt sensing receptors Fxr and Pxr.
Thus, although experimental evidence was consistent with the absence of any defect in the resorption. However, we detected no difference between wild-type and mutant mice in ileal expression levels of Asbt and Ilbp, the two proteins responsible for bile salt uptake and transport across the ileocyte. Since intestinal bile salt levels regulate Ilbp levels, these observations suggest that bile salt flux across the ileocyte is similar in wild-type and mutant mice. Therefore, the increased resorption may occur elsewhere in the enterohepatic circulation or involve a different mechanism.
In the context of increased bile salt resorption, the observed increased hydroxylation of TDC and consequent resistance to TDC-induced cholestasis in Atp8b1 mutant mice are striking.
The increased rehydroxylation is likely a response to increased levels of circulating bile salts.
The inability of humans to rehydroxylate secondary bile salts may underlie the severe consequences of ATP8B1 disease in humans. Significantly, ATP8B1 is expressed in the colon (35) , where resident bacteria produce secondary bile salts. Increased absorption of secondary bile salts in humans may thus account for the observed increased levels of hydrophobic bile salts in the bile and/or serum of patients with ATP8B1 mutations (11, 36) ; abnormal transhepatic flux of these toxic bile salts likely induces cholestasis and liver damage. 
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The possibility of increased intestinal bile salt resorption in Atp8b1 mutant mice is consistent with observed extrahepatic abnormalities in patients with severe ATP8B1 disease.
After successful liver transplantation, many such patients suffer from persistent diarrhea, unlike BSEP disease patients (17) (18) (19) 37) . Transplanted ATP8B1 disease patients (19), but not BSEP disease patients (A.S.K., unpublished data), develop steatosis in allograft livers; the transplanted normal liver thus appears suscept ible to damage when placed downstream of potentially deranged bile salt resorption in the ATP8B1-deficient intestine.
In addition to the intestine, increased bile salt resorption can occur in the biliary tract, including bile ducts and the gallbladder. ATP 8B1 is expressed in bile duct epithelial cells (cholangiocytes) more strongly than in hepatocytes (20) . Cholangiocytes lacking ATP8B1 might permit excessive shunting of hydrophobic biliary bile salts back to hepatocytes via the cholangioportal circulation (38, 39); our observation of increased Vdr in the Atp8b1 mutant liver upon cholate feeding indirectly supports this hypothesis, as VDR is activated by hydrophobic bile salts (31) . As VDR/Vdr expression is nearly absent in human and rodent hepatocytes, but relatively high in cholangiocytes (32), the observed increase in hepatic Vdr levels in cholate-fed Atp8b1 mutant mice could be a marker for the effects of bile salt challenge on Atp8b1-deficient bile duct epithelial cells. Since Asbt is also present in cholangiocytes, but not in hepatocytes, the reduced hepatic Asbt expression observed in cholate-fed mutants compared to control-fed wildtypes is also consistent with changes in cholehepatic bile salt shunting in Atp8b1 mutant mice.
Physiologic differences between mice and humans could explain the paradox of an identical mutation producing contrasting phenotypes -decreased bile salt secretion and severe cholestasis in humans, but enhanced bile salt secretion and resistance to the cholestatic effects of hydrophobic bile salts in mice. As in Atp8b1 mutant mice, in humans with ATP8B1 mutations, 
MATERIALS AND METHODS
Isolation of the mouse orthologue of ATP8B1
BLAST homology searching identified a mouse EST (GenBank AA242626) with 98% protein sequence identity to bp 3229-3694 of human ATP8B1 . The full-length Atp8b1 cDNA sequence was assembled using primer walking and R ACE (rapid amplification of cDNA ends) on mouse liver cDNA and was deposited in GenBank (accession number AY506548).
Generation of Atp8b1 G308V/G308V mutant mice
We constructed the tar geting vector from a 7.1 kb BamHI genomic DNA fragment, derived from a P1 clone (mouse 129/Sv ES cell DNA library, Genome Systems, St. Louis, MI), encompassing exons 9-12 of Atp8b1. The G923T point mutation was introduced into exon 10 by site-directed mutagenesis. A loxP-neo-loxP resistance cassette (43) was inserted into an intronic Bcl I restriction site. Linearized vector was electroporated into strain129/SvJae PC-3 ES cells carrying a male-germ-line specific Cre transgene (44) . Recombinant colonies were screened by Southern blot using 5' -and 3'-genomic probes and a neo probe and by PCR using primers specific for the G923T point mutation. Two independent heterozygous mutant ES cell clones injected into strain C57Bl/6 blastocysts yielded chimeric male mice, which transmitted the targeted allele when bred to C57Bl/6 females. Deletion of the loxP-flanked neo selection cassette from the targeted allele during germline transmission was confirmed by PCR. Chimeric founders bred to strain 129/SvImJ female mice (JAX, Bar Harbor, ME) produced mutant heterozygotes, which were intercrossed to produce Atp8b1 G308V/G308V mutants and wild-type controls.
In vivo experiments
Age-matched male mice aged 2-7 months were used in all experiments. Isoflurane anesthesia was used for blood collection by orbital puncture. Mice were fed standard rodent chow or, for 
Assays
Phospholipid, cholesterol, and bile salt concentrations in bile were determined enzymat ically (45) . Serum bilirubin levels and liver enzyme activities were measured by routine clinical chemistry. Serum, biliary and fecal bile salt composition was determined by HPLC/MS.
Western blotting
Protein extract preparation, SDS-PAGE, and Western blotting were performed as described (20) .
L. Klomp provided anti-ATP8B1 polyclonal antibody (20) . Anti-CPS (carbamoylphosphate synthetase) antibody, used as a reference, was a gift from W. Lamers.
Quantitative PCR analysis of gene expression
Tissue samples (liver and terminal ileum) were stored at -80°C in RNAlater™ (Qiagen, Hilden, Germany). Total RNA was extracted with Trizol reagent (Gibco BRL). cDNA was transcribed using random hexamers and MuLV reverse transcriptase (Gibco BRL). Real-time quantitative PCR was performed in triplicate on the ABI Prism 7900 analyzer at the UCSF Cancer Center
Genome Analysis Core Facility as previously described (46, 47 Figure 5b was the organ assayed; elsewhere, the repeated factor was time. 
Figure 2
Intravenous bile salt infusion reveals no impairment of bile salt secretion capacity and resistance to TDC-induced cholestasis in Atp8b1 G308V/G308V mutant mice. Gallbladders were cannulated and bile collected to deplete the endogenous bile salt pool. Subsequently, bile salts were infused intravenously at a stepwise increasing rate terminating with 60 min at the maximal rate of 2400 nmol/min/100g (tauroursodeoxycholate, TUDC), or 800 nmol/min/100g (taurodeoxycholate, alkaline phosphatase activity (ALP, U/L) in wild-type and Atp8b1 G308V/G308V mice on 0.5% cholate diet (n = 3-8). *P < 0.01, **P < 0.0005, ***P < 0.0001 (two-way repeated measures ANOVA). (E) Total serum bile salt (BS) levels (µM) in wild-type and Atp8b1 G308V/G308V mice on 0.5% cholate diet (n = 6-8). *P < 0.05, ***P < 0.001 (two-way repeated measures ANOVA). (F)
Serum bile salt composition of wild-type and Atp8b1 G308V/G308V mice on 0.5% cholate diet (n = 8). % taurocholate: wild-type 28% ± 14%; Atp8b1 G308V/G308V 86% ± 11%; P < 0.0003 (MannWhitney).
Figure 4
Cholate feeding enhances biliary bile salt output in Atp8b1 G308V/G308V mice. Gallbladders were cannulated at t = 0 and bile collected during 150 minutes of bile salt depletion, followed by 90 min of tauroursodeoxycholate (TUDC) intravenous infusion, as in Fig. 2A . Biliary bile salt (BS) output of wild-type and Atp8b1 G308V/G308V mice after 4 weeks on 0.5% cholate diet is shown (n = 6-8). Depletion phase: overall P < 0.0001 (two-way repeated measures ANOVA with Tukey's correction for multiple testing), TUDC infusion: no significant difference between wild -types and mutants.
Figure 5
Excess retention of orally administered 3 H-taurocholate in cholate-fed Atp8b1 G308V/G308V mice.
(A) Total 3 H levels (bile, liver, intestines) in wild-type (WT) and Atp8b1 G308V/G308V mice on control and 0.5% cholate diet, 4 days after oral administration of 1 µCi Expression in terminal ileum.
